FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
They pursuant to Section 10(4) of the Securities Exchange Act of 1554
or Costion 20(b) of the Investment Company Act of 1040

			or Section 30(n) of the investment Company Act of 1940					
	ess of Reporting Pe vestments Lto (First)		2. Issuer Name and Ticker or Trading Symbol <u>BELLICUM PHARMACEUTICALS, INC</u> BLCM]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify below) below)				
11007 WICKWOOD DRIVE		. ,	3. Date of Earliest Transaction (Month/Day/Year) 12/17/2014					
(Street) HOUSTON (City)	TX (State)	77024 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table I - Non	- Derivative Securities Acquired, Disposed of, or Benefic					

3. Transaction Code (Instr. 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned 7. Nature of Indirect Beneficial 1. Title of Security (Instr. 3) 2. Transaction Date 2A. Deemed Execution Date, (Month/Dav/Year) if any Following Reported Transaction(s) (Month/Day/Year) 8) Ownership (Instr. 4) (A) or (D) (Instr. 3 and 4) v Price Code Amount

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Warrant to Purchase Series C Preferred Stock (right to buy)	\$6	12/17/2014		x			333,536	08/22/2014	08/22/2019 ⁽¹⁾	Series C Preferred Stock	333,536	\$0.00	0	D	
Series C Convertible Preferred Stock	(2)	12/17/2014		x		333,536		(2)	(2)	Common Stock	196,197	(2)	196,197	D	

Explanation of Responses:

1. Upon the date immediately following the date of the effectiveness of the initial public offering of the Issuer, on or prior to March 31, 2015, this Warrant will be terminated if not previously exercised.

2. The Series C Convertible Preferred Stock (the "Preferred Stock") are convertible into the Issuer's common stock at a conversion rate of 1 share of common stock for each 1.7 shares of Preferred Stock and have no expiration date.

Remarks:



** Signature of Reporting Person

12/19/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.